GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sangamo Therapeutics Inc (NAS:SGMO) » Definitions » Margin of Safety % (DCF Dividends Based)

SGMO (Sangamo Therapeutics) Margin of Safety % (DCF Dividends Based) : N/A (As of May. 01, 2025)


View and export this data going back to 2000. Start your Free Trial

What is Sangamo Therapeutics Margin of Safety % (DCF Dividends Based)?

Margin of Safety % (DCF Dividends Based) = (Intrinsic Value: DCF (Dividends Based) - Current Price) / Intrinsic Value: DCF (Dividends Based).

Note: Discounted Dividend model is only suitable for companies who have a consistant distribution history with more than 5 years. If the company's dividends does not remain steady over a long period, results may not be accurate due to the low consistency. The model is also only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, the data will not be stored into our database.

Sangamo Therapeutics's Predictability Rank is 1-Star. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF Dividends Based) is not calculated.

Competitive Comparison of Sangamo Therapeutics's Margin of Safety % (DCF Dividends Based)

For the Biotechnology subindustry, Sangamo Therapeutics's Margin of Safety % (DCF Dividends Based), along with its competitors' market caps and Margin of Safety % (DCF Dividends Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Sangamo Therapeutics's Margin of Safety % (DCF Dividends Based) Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Sangamo Therapeutics's Margin of Safety % (DCF Dividends Based) distribution charts can be found below:

* The bar in red indicates where Sangamo Therapeutics's Margin of Safety % (DCF Dividends Based) falls into.


;
;

Sangamo Therapeutics Margin of Safety % (DCF Dividends Based) Related Terms

Thank you for viewing the detailed overview of Sangamo Therapeutics's Margin of Safety % (DCF Dividends Based) provided by GuruFocus.com. Please click on the following links to see related term pages.

Sangamo Therapeutics Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sangamo Therapeutics Inc (NAS:SGMO) » Definitions » Margin of Safety % (DCF Dividends Based)
Comparable Companies
TVRD INBX ACTU HURA INMB DMAC AARD TVGN RGLS KRRO VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX ALNY XBRU:UCB ONC BNTX XKRX:068270
Traded in Other Exchanges
0R1D:UK GBY:Germany GBY:Germany
Address
501 Canal Boulevard, Richmond, CA, USA, 94804
Website
https://www.sangamo.com
Sangamo Therapeutics Inc is a genomic medicine company committed to translating ground-breaking science into medicines that transform the lives of patients and families afflicted with serious neurological diseases. Its pipeline products include the Priority Neurology Pipeline offers Chronic Neuropathic Pain, Prion Disease, and Neurology; Partnered Programs offer Hemophilia A, Oncology, ALS/FTD, and Huntington's Disease; and Other Pipelines include Fabry Disease, Renal Transplant, Inflammatory Bowel Disease, and Multiple Sclerosis.
Executives
Biogen Inc. 10 percent owner 225 BINNEY STREET, CAMBRIDGE MA 02142
Beers Courtney director C/O SANGAMO THERAPEUTICS, INC., 7000 MARINA BOULEVARD, BRISBANE CA 94005
Margaret A Horn director 925 PAGE MILL ROAD, PALO ALTO CA 94304
Nathalie Dubois-stringfellow officer: SVP-Chief Development Officer C/O SANGAMO THERAPEUTICS, INC., 7000 MARINA BOULEVARD, BRISBANE CA 94005
John Markels director C/O SANGAMO THERAPEUTICS, INC., POINT RICHMOND TECH CTR, 501 CANAL BLVD., RICHMOND CA 94804
H Stewart Parker director
Biogen Ma Inc. 10 percent owner 225 BINNEY STREET, CAMBRIDGE MA 02142
Scott B. Willoughby officer: SVP, Gen. Counsel & Secretary 7000 MARINA BLVD, BRISBANE CA 94005
Gary Loeb officer: EVP & General Counsel 5885 HOLLIS ST., SUITE 100, EMERYVILLE CA 94608
Jason D. Fontenot officer: SVP, Chief Scientific Officer 7000 MARINA BLVD, BRISBANE CA 94005
Robert J. Schott officer: SVP, Head of Development 7000 MARINA BLVD, BRISBANE CA 94005
Rolf Andrew Ramelmeier officer: EVP, Technical Operations 7000 MARINA BLVD, BRISBANE CA 94005
Saira Ramasastry director 501 CANAL BLVD., RICHMOND CA 94804
Kenneth J. Hillan director C/O ACHAOGEN, INC., 7000 SHORELINE COURT, SUITE 371, SOUTH SAN FRANCISCO CA 94080
David Mark Mcclung officer: EVP Chief Business Officer 7000 MARINA BLVD, BRISBANE CA 94005